A Clinical Study to Check the Safety and Effectiveness of Botanical Extract Standardized for Iron + Vitamin C and Botanical Extract Standardized for Iron in Adult Human Subjects with Anemia or Iron-deficiency Anemia

NCT ID: NCT06096103

Last Updated: 2025-03-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-03

Study Completion Date

2024-02-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, double-blind, parallel, three-arms, placebo-controlled, safety and efficacy study of Botanical Extract Standardized for Iron + Vitamin C and Botanical Extract Standardized for Iron in adult human subjects with anemia or iron-deficiency anemia.

A total of up to 96 adult male and female subjects of age 26 to 55 years (32 subjects/arm) will be enrolled to get 90 evaluable subjects (30 subjects/arm) in the study

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The potential subjects will be screened as per the inclusion \& exclusion criteria only after obtaining written informed consent from the subjects. The adult female/male subjects will be instructed to visit the facility as per the below visits. There will be total of 4 visits in this study.

* Visit 01 (Within 30 Days): Screening procedure, informed consent obtain process, baseline evaluations, blood collection, urine collection.
* Visit 02 (Day 01): Enrolment, randomization, product distribution, subject diary distribution, blood collection.
* Visit 03 (Day 30 ± 2 Days): Treatment period, blood collection, evaluations, consumer's QoL product perception questionnaire, subject diary review, AE reporting (if any).
* Visit 04 (Day 60 ± 2 Days): End of study process, evaluation, blood collection, urine collection, consumer's QoL and product perception questionnaire, subject diary collection, test treatments accountability, AE reporting (if any).

Assessment of efficacy parameters before test treatment usage will be done on screening visit within 30 days of Day 01, on Day 01 and after test treatment usage will be done on Day 30 (± 2 Days) and Day 60 (± 2 Days).

Blood Parameter Analysis: Hemoglobin, Hematocrit, RBC, WBC, MCV, MCH, MCHC, Serum Iron, Serum ferritin, Transferrin, Transferrin Saturation, Total Iron Binding Capacity, Total Cholesterol, Triglycerides, Random Glucose, Serum Creatinine, Uric Acid, SGPT, SGOT, LDL, HDL, HBsAG, SOD.

Urine Parameter: Chemical Parameters - Albumin, Blood, Glucose, pH; Physcial Parameters - Colour, Appearance and Deposits.

QoL Product Perception: Fatigue, Mood, Sleepiness, GI Discomfort, Energy Level, Epigastric Discomfort, Nausea, Diarrhoea, Constipation

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia, Iron Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, Double-Blind, Parallel, Three-Arms, Placebo-Controlled
Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators
Double (Participant, Investigator) The study is double blind wherein neither the subjects nor the Investigator shall be aware of the test treatment allocation

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Take the test treatment once a day with food

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DIETARY_SUPPLEMENT

Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food

Botanical Extract Standardised for Iron + Vitamin C

The botanical extract standardised for iron and vitamin c is specially formulated for iron deficiency anaemia or anaemia. Vitamin C can promote the Iron absorption

Group Type EXPERIMENTAL

Botanical Extract Standardized for Iron + Vitamin C

Intervention Type DIETARY_SUPPLEMENT

Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food

Botanical Extract Standardised for Iron

The botanical extract standardised for iron is formulated for iron deficiency anaemia or anaemia

Group Type EXPERIMENTAL

Botanical Extract Standardised for Iron

Intervention Type DIETARY_SUPPLEMENT

Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

placebo

Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food

Intervention Type DIETARY_SUPPLEMENT

Botanical Extract Standardized for Iron + Vitamin C

Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food

Intervention Type DIETARY_SUPPLEMENT

Botanical Extract Standardised for Iron

Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: 26 to 55 years (both inclusive) at the time of consent.
2. Sex: Healthy males and non-pregnant/non-lactating females.
3. Subject suffering from iron deficiency anaemia of mild to moderate type (Hb range of 8-11mg/dl)
4. Subject must have negative Hepatitis B Surface Antigen (HBsAG)Test at screening.
5. Females of childbearing potential must have a reported negative urine pregnancy test.
6. If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
7. Subject able to remain on stable usages of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
8. Subject able to forgo changes in baseline medications and nutritional supplements during the study period.
9. Subjects are willing to give written informed consent and are willing to follow the study procedure.
10. Subjects who commit not to use prescribed or OTC medication containing iron supplements for treatment of iron deficiency or anemia except test treatments for the entire duration of the study.
11. Subjects who are willing to use test treatments throughout the study period.

Exclusion Criteria

1. Subject having other blood disease or any malignancy.
2. Subject with severe anemia (Hb \< 8mg/dl).
3. Subject having any other chronic illness.
4. Subject with history of allergy or sensitivity to the test treatment ingredients.
5. Subject has a history of alcohol or drug addiction.
6. Any other condition which could warrant exclusion from the study, as per the investigator's discretion.
7. Pregnant or breastfeeding or planning to become pregnant during the study period.
8. Subject with history of acute blood loss.
9. Subject having a history of surgery in last 3-6 months.
10. Subjects participating in other similar nutraceuticals, food, supplemental or therapeutic trials within the last four weeks.
Minimum Eligible Age

26 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Orgenetics, Inc.

INDUSTRY

Sponsor Role collaborator

NovoBliss Research Pvt Ltd

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Nayan Patel

Principal Investigator- Medical Director

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr Nayan K Patel

Role: PRINCIPAL_INVESTIGATOR

Medical Direcor

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NovoBliss Research Pvt.Ltd

Gandhinagar, Gujarat, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NB230024-OI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Natural Heart Health Supplement Trial
NCT06671769 NOT_YET_RECRUITING PHASE1